Importantly, such BAX-deficient lymphoma cells, unlike TRP53-deficient lymphoma cells, can still be potently killed by standard chemotherapeutic drugs, indicating a potential therapeutic strategy to overcome this mode of resistance to BH3-mimetic drugs. Here, TP53 is linked to lymphoma.